KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a custom-made vaccine using a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given together with two immunotherapy drugs to boost the immune system's attack on tumors. The study includ…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for Hard-to-Treat cancers: first human trial of TT125-802 begins
Disease control OngoingThis early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors (like lung cancer) that no longer respond to standard therapies. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for any tumor…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC